SWITCH TO DOR/ISL (100/0.75MG) QD FROM B/F/TAF: WEEK 48 RESULTS FROM A PHASE 3 TRIAL

Authors
Category Primary study
JournalTopics in Antiviral Medicine
Year 2023
This article has no abstract
Epistemonikos ID: ae505d80c4ceb82f2da68e9ca629e0fd42c4c4e8
First added on: Feb 15, 2025